+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Recent advances in quantitative proteomics as a sensitive tool to quantify drug transporters and drug metabolizing enzymes at the human blood-brain barrier

Recent advances in quantitative proteomics as a sensitive tool to quantify drug transporters and drug metabolizing enzymes at the human blood-brain barrier

Biologie Aujourd'hui 206(3): 177-183

Since its discovery at the beginning of the 20th century, the blood-brain barrier (BBB) has been considered for a long time as a "physical barrier" able to limit brain distribution of highly molecular weight and/or polar compounds. This early concept of an anatomical barrier between the blood and the brain was supported by the finding of unique tight junctions between the brain endothelial cells so that they formed a continuous wall preventing the paracellular diffusion of solutes. In the middle of the 50's, BBB has been proposed as a "biochemical barrier" able to control the supply of brain to essential nutriments. More recently, BBB was evidenced as a key element in controlling effects of central nervous system drugs, since it plays a critical role in the uptake and efflux of drugs from the blood to the brain, or vice versa, hence affecting their concentrations and effects in the central nervous system (CNS). The BBB has therefore been more recently defined as a "pharmacological barrier" since the endothelial cells were found to contain a range of metabolizing enzymes and transporters that control the rate and extent of drugs reaching the brain parenchyma via transcellular pathway. The emergence of new quantitative proteomic approaches allows quantifying these transporters and enzymes at the BBB, opening the way to identify new drugs that may be targeted to the brain.

(PDF emailed within 0-6 h: $19.90)

Accession: 055398519

Download citation: RISBibTeXText

PMID: 23171840

DOI: 10.1051/jbio/2012022

Related references

Hurdles with using in vitro models to predict human blood-brain barrier drug permeability: a special focus on transporters and metabolizing enzymes. Current Drug Metabolism 14(1): 120-136, 2013

Interplay of drug metabolizing CYP450 enzymes and ABC transporters in the blood-brain barrier. Current Drug Metabolism 12(8): 732-741, 2012

Alternative fusion protein strategies to express recalcitrant QconCAT proteins for quantitative proteomics of human drug metabolizing enzymes and transporters. Journal of Proteome Research 12(12): 5934-5942, 2014

Recent advances in the quantification of drug metabolizing enzymes and transporters by proteomic approach. Yao Xue Xue Bao 50(6): 668-674, 2016

Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Molecular Pharmaceutics 8(4): 1332-1341, 2012

MicroRNAs as regulators of drug transporters, drug-metabolizing enzymes, and tight junctions: implication for intestinal barrier function. Pharmacology and Therapeutics 143(2): 217-224, 2015

Shed human enterocytes as a tool for the study of expression and function of intestinal drug-metabolizing enzymes and transporters. Clinical Pharmacology and Therapeutics 71(3): 131-140, 2002

Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. Journal of Neurochemistry 117(2): 333-345, 2011

Inter-Individual and Regional Variability in Drug Transporter Abundance at the Human Blood-Brain Barrier Measured by Quantitative Targeted Proteomics. Clinical Pharmacology and Therapeutics 2019, 2019

A new aspect of the protective functions of the blood-brain barrier: activities of four drug-metabolizing enzymes in isolated rat brain microvessels. Life Sciences 42(24): 2515-2523, 1988

Proteomics and the blood-brain barrier: how recent findings help drug development. Expert Review of Proteomics 13(3): 251-258, 2016

Impact of transporters and enzymes from blood-cerebrospinal fluid barrier and brain parenchyma on CNS drug uptake. Expert Opinion on Drug Metabolism and Toxicology 14(9): 961-972, 2018

In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters. Drug Metabolism and Disposition: the Biological Fate of Chemicals 41(3): 668-681, 2013

Potential risks resulting from fruit/vegetable-drug interactions: effects on drug-metabolizing enzymes and drug transporters. Journal of Food Science 76(4): R112-R124, 2012

Expression of clinically relevant drug-metabolizing enzymes along the human intestine and their correlation to drug transporters and nuclear receptors: An intra-subject analysis. Basic and Clinical Pharmacology and Toxicology 2018, 2018